Asialoglycoproteins

Endogenous glycoproteins from which SIALIC ACID has been removed by the action of sialidases. They bind tightly to the ASIALOGLYCOPROTEIN RECEPTOR which is located on hepatocyte plasma membranes. After internalization by adsorptive ENDOCYTOSIS they are delivered to LYSOSOMES for degradation. Therefore receptor-mediated clearance of asialoglycoproteins is an important aspect of the turnover of plasma glycoproteins. They are elevated in serum of patients with HEPATIC CIRRHOSIS or HEPATITIS.

Also Known As:

Networked: 57 relevant articles (0 outcomes, 4 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Ding, Yuanyuan: 2 articles (04/2017 - 12/2014)
2.	Han, Jian: 2 articles (04/2017 - 12/2014)
3.	Han, Jingtian: 2 articles (04/2017 - 12/2014)
4.	Tian, Baocheng: 2 articles (04/2017 - 12/2014)
5.	Zhang, Jing: 2 articles (04/2017 - 12/2014)
6.	Sharma, Praveen: 1 article (05/2022)
7.	G U, Preethi: 1 article (12/2020)
8.	Joseph, Manu M: 1 article (12/2020)
9.	Pillai, K Raveendran: 1 article (12/2020)
10.	R, Shiji: 1 article (12/2020)

Related Diseases

1.	Hepatocellular Carcinoma (Hepatoma) 06/01/1987 - "The receptor for asialoglycoproteins (ASGPR) was localized in human hepatoma Hep G2 cells by means of quantitative immunoelectron microscopy. " 10/01/1985 - "The asialoglycoprotein (ASGP) receptor isolated from human liver and from the human hepatoma cell line HepG2 migrates on NaDodSO4 gel electrophoresis as a single species of 45,000 daltons. " 12/01/1983 - "Rapid acidification of endocytic vesicles containing asialoglycoprotein in cells of a human hepatoma line." 11/01/1983 - "The human hepatoma cell line, Hep G2, was used as a model system to delineate the morphological aspects of receptor-mediated endocytosis of asialoglycoproteins (ASGP). " 06/01/1985 - "The amount of serum asialoglycoproteins also correlated with survival time in fatal cases of cirrhosis and/or hepatocellular carcinoma. "
2.	Neoplasms (Cancer) 01/01/2013 - "In vitro drug release studies demonstrated a controlled drug release profile with increased release at acidic pH. Remarkably, tumor proliferation assays showed that PTX-loaded mixed copolymer NPs inhibited asialoglycoprotein (ASGP) receptor positive HepG2 cell proliferation in a concentration-dependent manner in comparison with ASGP receptor negative BGC-823 cells. " 02/01/2016 - "-FI-PEG-LA/DOX can specifically target cancer cells overexpressing asialoglycoprotein (ASGPR) receptors and exert growth inhibition effect to the cancer cells. " 04/01/1993 - "Altered expression of asialoglycoprotein (ASGP) receptors on hepatocytes has been reported during hepatic neoplasia mostly in animal models. " 01/01/1990 - "The analysis presented discards the hypothesis advanced by Schwartz et al. that at high concentrations of asialoglycoproteins in the medium the recycling of receptors of the tumor cells of HepG2 is inhibited." 12/01/1984 - "There was a close correlation between serum asialoglycoprotein levels and the size of the tumor mass in patients with liver cell carcinoma. "
3.	Liver Diseases (Liver Disease) 02/01/2014 - "Even at lower doses in which radiation-induced liver disease was mild or nonexistent, latent and significant injury to hepatocytes was demonstrated by asialoglycoprotein-mediated functional imaging. " 04/01/1997 - "Hepatic lobar differences in progression of chronic liver disease: correlation of asialoglycoprotein scintigraphy and hepatic functional reserve." 03/01/1985 - "Since the serum of patients with liver disease often contains large amounts of several desialylated glycoproteins, the aim of the present studies was to characterize circulating TBG and to examine the possible presence of desialylated TBG (dTBG) in 24 patients with a variety of hepatobiliary diseases and selected on the basis of elevated serum levels of desialylated glycoproteins. " 06/01/1985 - "The correlation between the amount of asialoglycoproteins and results of conventional liver function tests was studied in patients with chronic liver diseases, with or without hepatocellular carcinoma. " 06/01/1985 - "Clinical application of the measurement of serum asialoglycoproteins to estimate residual liver function in patients with chronic liver diseases with or without hepatocellular carcinoma."
4.	Digestive System Diseases 03/01/1985 - "Since the serum of patients with liver disease often contains large amounts of several desialylated glycoproteins, the aim of the present studies was to characterize circulating TBG and to examine the possible presence of desialylated TBG (dTBG) in 24 patients with a variety of hepatobiliary diseases and selected on the basis of elevated serum levels of desialylated glycoproteins. "
5.	Fibrosis (Cirrhosis) 04/01/1992 - "Serum concentrations of asialoglycoproteins are increased in cirrhosis. " 06/01/1985 - "The amount of serum asialoglycoproteins also correlated with survival time in fatal cases of cirrhosis and/or hepatocellular carcinoma. " 12/01/1984 - "Our results suggest that decreases in the asialoglycoprotein receptor levels may lead to an accumulation of serum asialoglycoproteins in patients with cirrhosis or liver cell carcinoma, or both." 01/01/1988 - "In the absence of significant hepatic cytolysis, the enhanced level of seric corrinoids in cirrhosis could be partly explained by a competitive inhibition of the liver uptake of haptocorrin by circulating asialoglycoproteins, including IgA."

Related Drugs and Biologics

1.	Ligands
2.	Gold Colloid (Colloidal Gold)
3.	polymeric IgA
4.	Asialoglycoprotein Receptor
5.	Galactose (Galactopyranose)
6.	Contrast Media
7.	Acids
8.	Indicators and Reagents (Reagents)
9.	Glycoproteins (Glycoprotein)
10.	Bile Acids and Salts (Bile Acids)

Related Therapies and Procedures

1.	Intravenous Injections
2.	Lasers (Laser)
3.	Drug Therapy (Chemotherapy)